Publications by authors named "Ushna Gul"
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been developed to manage type 2 diabetes mellitus. Although, in the last 10 years, the use of GLP-1 RAs, especially semaglutide and liraglutide, has increased, its clinical implications and how it affects metabolic parameters have yet to be fully consolidated. This narrative review explores the metabolic effects of GLP-1 RAs in weight management, blood glucose, cardiovascular health, lipid profiles, and blood pressure.
View Article and Find Full Text PDFNonalcoholic steatohepatitis (NASH) is a progressive form of nonalcoholic fatty liver disease (NAFLD) associated with metabolic syndrome and increased cardiovascular risk. Resmetirom, a novel liver-directed selective thyroid hormone receptor-β (THR-β) agonist, has shown promise in addressing both hepatic and systemic lipid metabolism. This systematic review and meta-analysis aimed to evaluate the efficacy of resmetirom in improving cholesterol levels in NASH patients.
View Article and Find Full Text PDFArticle Synopsis
- Type 2 diabetes (T2DM) increases the risk of cardiovascular diseases, prompting a study comparing the cardiovascular benefits of two medications, dapagliflozin and empagliflozin, known as SGLT2 inhibitors.
- A comprehensive analysis of twelve studies found that while dapagliflozin was better at preventing atrial fibrillation compared to empagliflozin, no significant differences were noted in other cardiovascular outcomes like major adverse events and mortality.
- Both medications were effective at reducing cardiovascular risks in T2DM patients, but dapagliflozin's lower atrial fibrillation risk could influence treatment choices, especially for at-risk individuals.